Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

A novel pharmaceutical treatment for nonalcoholic fatty liver disease

Obiettivo

Development of anti-microRNA therapeutic for nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) initiates with excessive accumulation of liver triglycerides and progresses to nonalcoholic steatohepatitis (NASH), cirrhosis and liver cancer while also modifying brain metabolism. However, NAFLD pathogenesis, the corresponding impact on the brain and the links between them, are poorly understood. In addition NAFLD is largely untreatable. We have discovered that excess microRNA (miR)-132 initiates NAFLD and that miR-132 suppression by oligonucleotide antisense treatment effectively reverses NAFLD in acquired and inherited mouse models. Here we to develop this discovery as a novel and effective pharmaceutical for the treatment of NAFLD, a serious and widespread disease for which there is at present no pharmacological treatment.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

ERC-POC - Proof of Concept Grant

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2016-PoC

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

THE HEBREW UNIVERSITY OF JERUSALEM
Contributo netto dell'UE
€ 150 000,00
Indirizzo
EDMOND J SAFRA CAMPUS GIVAT RAM
91904 Jerusalem
Israele
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 150 000,00

Beneficiari (1)